title: [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
abstract: OBJECTIVE
  Hormone and Herceptin therapy for metastatic breast cancer is commonly based on expression of estrogen receptor (ER) and progestin receptor (PR), and over-expression of HER-2 in primary breast cancer, but studies comparing receptor statuses in primary and metastatic focuses of the same patient are limited. This study was designed to investigate discordance of ER, PR,and HER-2 statuses between primary and metastatic focuses of breast cancer.
  
  
  METHODS
  Immunohistochemistry assay was used to detect expression of ER, PR, and HER-2 receptor in primary and metastatic focuses of 65 cases of breast cancer.
  
  
  RESULTS
  Positive rate of ER in primary focuses was 56.9% (37/65), significantly higher than that in metastatic focuses (33.8%, 22/65)(P< 0.01); while positive rates of PR and HER-2 receptor have no significant difference between primary and metastatic focuses. Total discordance rates of ER, PR, and HER-2 were 35.4%, 29.2%, and 16.9%, respectively.
  
  
  CONCLUSIONS
  Difference in expression level of ER between primary and metastatic focuses of breast cancer was significant, while differences of expression of PR, and HER-2 wasn't significant, but we still should think highly of the expression differences of ER,PR,and HER-2 in our clinical practices.
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, P.R. China.
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Zhong-Zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: Dong-Geng
authors.initials: DG
authors.lastname: Liu
authors.forename: Tong-Yu
authors.initials: TY
authors.lastname: Lin
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Zhong-Jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Teng
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone